Kaleido Biosciences Inc (NASDAQ:KLDO) was the target of a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 1,820,000 shares, an increase of 20.5% from the December 15th total of 1,510,000 shares. Approximately 20.2% of the company’s stock are sold short. Based on an average daily trading volume, of 123,900 shares, the short-interest ratio is presently 14.7 days.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. FMR LLC acquired a new stake in Kaleido Biosciences during the first quarter valued at $25,143,000. BlackRock Inc. acquired a new stake in Kaleido Biosciences during the second quarter valued at $2,835,000. Vanguard Group Inc. acquired a new stake in Kaleido Biosciences during the second quarter valued at $1,061,000. State Street Corp boosted its position in Kaleido Biosciences by 14.9% during the third quarter. State Street Corp now owns 79,475 shares of the company’s stock valued at $598,000 after purchasing an additional 10,300 shares during the last quarter. Finally, Bainco International Investors acquired a new stake in Kaleido Biosciences during the third quarter valued at $333,000. 79.73% of the stock is owned by hedge funds and other institutional investors.
KLDO has been the subject of several recent analyst reports. Chardan Capital reaffirmed a “buy” rating on shares of Kaleido Biosciences in a research report on Thursday, September 19th. Zacks Investment Research cut Kaleido Biosciences from a “buy” rating to a “hold” rating in a research report on Thursday, January 2nd. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $15.71.
Shares of Kaleido Biosciences stock opened at $5.14 on Wednesday. The business has a fifty day simple moving average of $6.02 and a 200-day simple moving average of $7.46. Kaleido Biosciences has a 12 month low of $4.61 and a 12 month high of $19.00.
Kaleido Biosciences (NASDAQ:KLDO) last released its quarterly earnings data on Wednesday, October 30th. The company reported ($0.74) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.15. As a group, analysts predict that Kaleido Biosciences will post -3.38 earnings per share for the current fiscal year.
About Kaleido Biosciences
Kaleido BioSciences, Inc develops microbiome metabolic therapies. It offers treatment for hyperammonemia, a metabolic condition generally characterized by elevated levels of ammonia in the blood; infections caused by multi-drug resistant bacteria; chronic kidney disease; atherosclerotic cardiovascular disease; and drug or disease induced diarrhea.
Read More: Dividend Aristocrat Index
Receive News & Ratings for Kaleido Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kaleido Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.